These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Adverse events associated with intravenous immunoglobulin therapy. Hamrock DJ Int Immunopharmacol; 2006 Apr; 6(4):535-42. PubMed ID: 16504916 [TBL] [Abstract][Full Text] [Related]
6. [Adverse effects of administration of intravenous human immunoglobulins]. Bednarík J; Kadanka Z Cas Lek Cesk; 1999 Nov; 138(21):647-9. PubMed ID: 10746020 [TBL] [Abstract][Full Text] [Related]
7. Pharmacy considerations for the use of IGIV therapy. Shah S Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S5-11. PubMed ID: 16100386 [TBL] [Abstract][Full Text] [Related]
8. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Brannagan TH Neurology; 2002 Dec; 59(12 Suppl 6):S33-40. PubMed ID: 12499469 [TBL] [Abstract][Full Text] [Related]
9. Risks associated with the use of intravenous immunoglobulin. Pierce LR; Jain N Transfus Med Rev; 2003 Oct; 17(4):241-51. PubMed ID: 14571392 [TBL] [Abstract][Full Text] [Related]
10. Smallpox vaccination and adverse reactions. Guidance for clinicians. Cono J; Casey CG; Bell DM; MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510 [TBL] [Abstract][Full Text] [Related]
11. Adverse Effects of Immunoglobulin Therapy. Guo Y; Tian X; Wang X; Xiao Z Front Immunol; 2018; 9():1299. PubMed ID: 29951056 [TBL] [Abstract][Full Text] [Related]
12. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Günther G; Dreger B Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863 [TBL] [Abstract][Full Text] [Related]
13. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease. Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654 [TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin for the treatment of childhood encephalitis. Iro MA; Martin NG; Absoud M; Pollard AJ Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011367. PubMed ID: 28967695 [TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Hooper JA Immunol Allergy Clin North Am; 2008 Nov; 28(4):765-78, viii. PubMed ID: 18940573 [TBL] [Abstract][Full Text] [Related]
16. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363 [TBL] [Abstract][Full Text] [Related]
17. Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Dodd RY Clin Exp Immunol; 1996 May; 104 Suppl 1():31-4. PubMed ID: 8625541 [TBL] [Abstract][Full Text] [Related]
18. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Cherin P; Marie I; Michallet M; Pelus E; Dantal J; Crave JC; Delain JC; Viallard JF Autoimmun Rev; 2016 Jan; 15(1):71-81. PubMed ID: 26384525 [TBL] [Abstract][Full Text] [Related]
19. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Gürcan HM; Ahmed AR Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614 [TBL] [Abstract][Full Text] [Related]
20. Not all intravenous immunoglobulin preparations are equally well tolerated. Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]